Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411


Share on StockTwits

Investor Ideas Potcasts #578, Cannabis News and Stocks on the Move; Interview with CEO of Albert Labs - improving patient access to psychedelic assisted therapies

 

Delta, Kelowna, BC - June 22, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/062221-StocksToWatch.mp3

Investor Ideas Potcasts #578, Cannabis News and Stocks on the Move; Interview with CEO of Albert Labs - improving patient access to psychedelic assisted therapies

SHARE PODCAST:      

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today's podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today' s podcast Investorideas interviews Dr. Michael Raymont, CEO of Albert Labs, a laboratory based, clinical research and drug development enterprise, focused on improving patient access to psychedelic assisted therapies through accelerated regulatory approval pathways, where we discussed the companies unique approach through Real World Evidence studies, the psychedelic landscape in the EU and UK as well as expectations around how the medical side of psychedelics will continue to develop.

Dr. Raymont' s career has spanned leadership roles in venture capital, agricultural and healthcare investment, tech company leadership and senior Government service, where he ran the National Research Council (NRC), Canada' s largest R&D organization.  With a background in both science and business, Dr. Raymont has advised corporations and governments, worked extensively internationally, and has sat on the boards of over 50 public and private companies.

The company recently sent its application for listing on the Canadian Securities Exchange (" CSE" ). The Listing Statement submission will initiate a consulting phase by the CSE with the Company in preparation for subsequent listing of the common shares in the capital of the resulting issuer Albert Labs, subject to satisfying requirements of the CSE. While there can be no guarantee the Common Shares will be successfully listed on the CSE, Albert Labs is working towards the listing execution of definitive documents and closing with respect to the RTO definitive agreement dated March 5th.

Chand Jagpal, the Chief Operations Officer of Albert Labs, stated " The much anticipated submission of the listing statement represents a significant milestone for Albert Labs. We' re excited to move towards our goal of becoming a public company to attract growth capital and enable Albert Labs to continue towards its goal of being a worldwide leader and provide accelerated access to psychedelics medicines and therapy"

When asked what separates Albert Labs from other competitors in the psychedelic space, Dr. Michael Raymont commented, " Albert labs is differentiated from our competitors by a unique strategy, and that unique strategy uses an asset light model and ,very important for investors, we are really focussed on speed to market. Speed to market means speed to revenues, and speed to revenues means faster returns for investors."

" So how are we bringing these products to market? We' re using an approach that is Real World Evidence studies. Real World Evidence studies differ from clinical trials. Here' s the essential thing for investors, the difference, apart from the actual pathway towards regulatory approval, is the fact that Real World Evidence trials can be run and approved in a matter of months for a few million dollars rather than a matter of many years in most cases for clinical trial approved drugs and the common number today for clinical blockbuster drugs is roughly a half a billion dollars. So it' s risk mitigated, it' s fast to market, faster to revenues and it is safe," Raymont continued.

Albert Labs, unlike some of its competitors today, is also much more focussed when it comes to the specific ailments they look to address through psychedelics as Raymont mentioned, " Real World Evidence trials tend to focus on a pretty specific outcome and a pretty specific problem. So in our case at Albert Labs, we are focussed on treating anxiety in cancer patients, we are not trying to treat general anxiety. We may be able to treat other anxiety related situations beyond cancer but we would have to go through other trials in order to have the medicine used for something else."

Dr. Michael Raymont went on to discuss the benefits of focussing on the UK and EU initially, growing interest from physicians and the mainstream medical community, which specific psychedelic compounds the company aims to work with initially and in the future of psychedelics when it comes to the difference between the medicinally focussed segment of the industry and the segment pushing for more of a recreational model.

To find out more information about Albert Labs click here.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes (Apple Podcasts), Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Play Music and most audio platforms available.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea's original branded content includes podcasts and columns: Crypto Corner, Play by Play sports and stock news, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast, Cleantech and Climate Change, Exploring Mining, Betting on Gaming Stocks Podcast and the AI Eye Podcast.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/investorideas_potcast/

Download our Mobile App for iPhone and Android

Contact Investorideas.com

800-665-0411


Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com